The nested case-control study in cardiology

American Heart Journal

Volumn 146, Issue 4, 2003, Pages 581-590

  Essebag, Vidal ^a,b   Genest Jr , Jacques ^a   Suissa, Samy ^b   Pilote, Louise ^a,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; STEROID;

ARTICLE; CARDIOLOGY; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DECISION MAKING; DRUG SCREENING; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; ORGANIZATION; PRIORITY JOURNAL; PUBLICATION; RISK FACTOR; SIDE EFFECT;

EID: 0142057099     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00512-X     Document Type: Article

References (54)

1. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-5.
2. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998;97:1095-102.
3. Rothman KJ, Greenland S, editors. Modern Epidemiology, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1998.
4. Mantel N. Synthetic retrospective studies and related topics. Biometrics 1973;29:479-86.
5. Miettinen OS. The "case-control" study: valid selection of subjects. J Chron Dis 1985;38:543-8.
6. Wacholder S, McLaughlin JK, Silverman DT, et al. Selection of controls in case control studies: I: principles. Am J Epidemiol 1992;135:1019-28.
7. Wacholder S, Silverman DT, McLaughlin JK, et al. Selection of controls in case control studies: II: types of controls. Am J Epidemiol 1992;135:1029-41.
8. Wacholder S, Silverman DT, McLaughlin JK, et al. Selection of controls in case control studies: III: design options. Am J Epidemiol 1992;135:1042-50.
9. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 1959;22:719-48.
10. Ernster VL. Nested case-control studies. Prev Med 1994;23:587-90.
11. Kupper LL, McMichael AJ, Spirtas R. A hybrid epidemiologic study design useful in estimating relative risk. J Am Stat Assoc 1975;70:524-8.
12. Liddell FDK, McDonald JC, Thomas DC. Methods of cohort analysis: appraisal by application to asbestos mining. J R Stat Soc Ser A 1977;140:469-91.
13. Breslow NE, Lubin JH, Marek P, et al. Multiplicative models and cohort analysis. J Am Stat Assoc 1983;78:1-12.
14. Egan-Baum E, Miller BA, Waxweiler RJ. Lung cancer and other mortality patterns among foundrymen. Scand J Work Environ Health 1981;7(4 Suppl):147-55.
15. Marsh GM. Mortality among workers from a plastics producing plant: a matched case-control study nested in a retrospective cohort study. J Occup Med 1983;25:219-30.
16. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984;40:63-75.
17. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. New York: Wiley; 1994.
18. Lubin JH. Extensions of analytic methods for nested and population-based incident case-control studies. J Chron Dis 1986;39:379-88.
19. Robins JM, Gail MH, Lubin JH. More on "biased selection of controls for case-control analyses of cohort studies." Biometrics 1986;42:293-9.
20. White E, Hunt JR, Casso D. Exposure measurement in cohort studies: the challenges of prospective data collection. Epidemiologic Reviews 1998;20:43-56.
21. Gail M, Williams R, Byar DP, et al. How many controls? J Chron Dis 1976;29:723-31.
22. Ury H. Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data. Biometrics 1975;31:643-9.
23. Goldstein L, Langholz B. Asymptotic theory for nested case-control sampling in the Cox regression model. Ann Stat 1992;20:1903-28.
24. Pang D. A relative power table for nested matched case-control studies. Occup Environ Med 1999;56:67-9.
25. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986,73:1-12.
26. Langholz B, Thomas DC. Nested case-control and case-cohort methods of sampling from a cohort: a critical comparison. Am J Epidemiol 1990;131:169-76.
27. Wacholder S. Practical considerations in choosing between the case-cohort and nested case-control designs. Epidemiology 1991;2:155-8.
28. Suissa S, Edwardes MD, Boivin JF. External comparisons from nested case-control designs. Epidemiology 1998;9:72-8.
29. Wacholder S, Boivin JF. External comparisons with the case-cohort design. Am J Epidemiol 1987;126:1198-209.
30. Boushey CJ, Beresford AA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.
31. Eikelboom JW, Lonn E, Genest JJ, et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Int Med 1999;131:363-75.
32. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988;71:227-33.
33. Genest JJ, McNamara JR, Salem DN, et al. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-9.
34. Ubbink JB, Vermaak WJH, Bennett JM, et al. The prevalence of hyperhomocysteinemia and hypercholesterolemia in angiographically defined coronary artery disease. Klin Wochenschr 1991;69:527-34.
35. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early onset coronary artery disease. Am J Clin Nutr 1994;59:940-8.
36. Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552-61.
37. von Eckardstein A, Malinow MR, Upson B, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Atheroscler Thromb 1994;14:460-4.
38. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
39. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19.
40. Arnesen E, Refsum H, Bonaa KH, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
41. Verhoef P, Hennekens CH, Allen RH, et al. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997;79:799-801.
42. Evans RW, Shaten BJ, Hempel JD, et al. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol 1997;17:1947-53.
43. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-7.
44. Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam study. Arch Intern Med 1999;159:38-44.
45. Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999;82:448-54.
46. Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovasćular disease among postmenopausal women. JAMA 1999;281:1817-21.
47. Voutilainen S, Lakka TA, Hamelahti P, et al. Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio ischaemic heart disease risk factor study. J Intern Med 2000;248:217-22.
48. The Homocysteine Studies Collaboration. Homocysteine and the risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
49. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178-82.
50. International Task Force for the Prevention of Coronary Artery Disease. Coronary artery disease: reducing the risk. Nutr Metab Cardiovasc Dis 1998;8:229.
51. Genest J Jr. Emerging risk factors associated with cardiovascular diseases: Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases. Can J Cardiol 1999;15(Suppl G):73-6G.
52. Heart and Stroke Foundation of Canada. A statement on plasma homocyst(e)ine and cardiovascular disease. Can J Cardiol 2001;17:763-4.
53. Booth GL, Wang EEL, with the Canadian Task Force on Preventive Health Care. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. CMAJ 2000;163:21-9.
54. Genest JJ, Audelin MC, Lonn E. Homocysteine: to screen and treat or to wait and see? CMAJ 2000;163:37-8.